Revenue Growth Might Change The Case For Investing In Hims & Hers Health Stock (HIMS)
Simply Wall St·September 25, 2026
Hims & Hers Health reported 38% revenue growth after acquiring Eucalyptus and raised full year guidance, while management flagged weaker margins and pressure on cash flow in the near term. The combination of faster top line expansion with falling profitability and cash generation suggests the business model is being stress tested by higher operating and integration costs. We will look at how Hims & Hers Health's investment narrative is affected by strong revenue growth alongside declining...
This article was sourced from Simply Wall St. Read the full article at the original publisher.
Read full article at Simply Wall St →